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Inhibition of TGFBIp Expression by Lithium:
Implications for TGFBI-Linked Corneal
Dystrophy Therapy
Seung-Il Choi,1,2 Bong-Yoon Kim,1,2 Shorafidinkhuja Dadakhujaev,1,2 James V. Jester,3
Hyunmi Ryu,1,2 Tae-im Kim,1,2 and Eung Kweon Kim1,2,4,5
PURPOSE. The purpose of this study was to investigate the effects
and molecular mechanisms of lithium on inhibition of TGFBIp
expression as a potential therapy for TGFBI-linked corneal dystro-
phy.
METHODS. Primary culture corneal fibroblasts were isolated from
the corneas of healthy subjects and patients with granular corneal
dystrophy type 2 (GCD2) with a homozygous mutation in TGFBI
R124H. Levels of TGFBIp and its mRNA in corneal fibroblasts
treated with various lithium (LiCl) concentrations were analyzed
by Western blot, RT-PCR, and quantitative real-time PCR.
RESULTS. LiCl treatment reduced the expression levels of normal
and mutant TGFBIp in a dose- and a time-dependent manner.
Furthermore, TGF-1–induced TGFBIp expression decreased by
35% and 67% after treatment with 5 mM and 10 mM LiCl, respec-
tively. LiCl decreased the level of pSmad3 (S423/425) in a dose-
dependent manner. Furthermore, LiCl increased the level of
pGSK-3/ (S21/9) in a dose-dependent manner. Also observed
was the interaction between GSK-3 and Smad3, which was
enhanced by lithium. In addition, Western blot analysis showed
that the ratio of LC3-II/LC3-I in corneal fibroblasts increased after
LiCl treatment. Cell viability at different doses was greater than
98%, indicating that LiCl did not induce significant corneal fibro-
blast death. Finally, the observed attenuating effects of LiCl on
TGFBIp expression were not the results of cell death.
CONCLUSIONS. The accumulation of mutant TGFBIp ultimately
leads to the histopathologic and clinical manifestations associ-
ated with TGFBI-linked corneal dystrophy. These data strongly
suggest that lithium may be used for the prevention or treat-
ment of this disease. (Invest Ophthalmol Vis Sci. 2011;52:
3293–3300) DOI:10.1167/iovs.10-6405
Transforming growth factor-–induced gene protein (TGFBIp),also known as ig-h3 protein, is secreted in response to
transforming growth factor- (TGF-) in human adenocarci-
noma cells and other cell types.1 In addition, this protein
exhibits tumor suppressive activity.2,3 More recently, reports
have shown that TGFBIp deficiency in mice induces cell pro-
liferation and spontaneous tumor development.4 The TGFBI
gene encodes a highly conserved 683-amino acid protein that
contains a secretory signal sequence and an Arg-Gly-Asp motif
that serves as a ligand recognition site for integrins.1 TGFBIp is
a component of the extracellular matrix, where it mediates cell
adhesion and migration by interacting with integrins.5–7
Granular corneal dystrophy type 2 (GCD2, also called Avel-
lino corneal dystrophy) is an autosomal dominant disorder
caused by a point mutation (R124H) in the TGFBI gene on
chromosome 5q31.1 Age-dependent progressive accumulation
of hyaline and amyloid in the corneal stroma is a hallmark of
GCD2, which is characterized by TGFBIp production in the
corneal epithelia and stroma, thereby interfering with corneal
transparency.1,8,9 To date, 38 mutations in the TGFBI gene
have been implicated in corneal dystrophies. Interestingly,
different mutations cause unique corneal dystrophy pheno-
types. Thus, though R124H is associated with GCD2, R124C is
associated with lattice corneal dystrophy type 1, R555W is
associated with granular corneal dystrophy type 1, and R555Q
is associated with Thiel-Behnke corneal dystrophy.10
Glycogen synthase kinase-3 (GSK-3) is an intracellular enzyme
involved in several cellular events.11 In particular, GSK-3 is well
established as a component of the Wnt signaling pathway. Bind-
ing of Wnts to their receptors results in GSK-3 inhibition and a
subsequent increase in -catenin levels.12,13 In addition, GSK-3 is
regulated by other signaling pathways, including those involving
AKT, and also serves as an upstream regulator of other transcrip-
tion factors and cellular proteins.11,14,15
GSK-3 inactivation generally results in antiapoptosis. A num-
ber of studies have demonstrated that lithium inhibits GSK-
3,16–21 and direct inhibition of GSK-3 activity by lithium has
been proved.18,19 GSK-3 is generally considered to play a pro-
apoptotic role, and its inhibition results in cytoprotection.22
Lithium also indirectly inhibits GSK-3 by triggering the phos-
phorylation of GSK-3 at Ser21/Ser9.23–25 Increasing evidence
suggests that lithium elicits its neuroprotective effects primar-
ily by inhibiting GSK-3.26 Besides direct inhibition, lithium can
inhibit GSK-3 indirectly through the phosphorylation of
GSK-3 at Ser21 and GSK-3 at Ser9 by multiple mechanisms,
including the activation of PKA,27 phosphatidylinositol 3-ki-
nase (PI3-K)-dependent AKT,23 protein kinase C (PKC),28 and
GSK-3 autoregulation.25,29
Recent reports demonstrated that the transcription factor
Smad3/4 is a novel GSK-3 target in neurons.30 Smad3/4 is a
downstream mediator of TGF-–mediated signaling path-
ways.31 Binding of TGF- to its serine/threonine kinase recep-
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tor leads to Smad2 and Smad3 phosphorylation. Phosphory-
lated Smad (pSmad) proteins then form a complex with Smad4
followed by translocation to the nucleus, where they interact
with other gene-specific transcription factors to regulate gene
expression.31,32 Smad3/4 plays a prominent role in regulating
the expression of proteins involved in neuronal survival/death,
differentiation, and plasticity.33,34 Studies have demonstrated
that TGF- can induce the phosphorylation of Smad3 at
Thr179, Ser204, and Ser208. Furthermore, GSK-3 phosphory-
lates Smad3 directly at Ser204.
These data suggest that the inhibition of mutant TGFBIp
(mut-TGFBIp) production through the regulation of TGF- sig-
naling with GSK-3 inhibitors may be a potential therapy for
TGFBI-linked corneal dystrophy. Therefore, we investigated
the effects of lithium treatment on TGFBIp expression. We
found that these treatments reduced TGFBIp expression dra-
matically in corneal fibroblasts. To our knowledge, this is the
first demonstration of decreased TGFBIp expression mediated
through the inhibition of TGF- signaling by lithium. These
results suggest that the use of clinical trials of lithium to treat
TGFBI-linked corneal dystrophy is a rational strategy.
MATERIALS AND METHODS
Materials
LiCl and KCl were obtained from Sigma-Aldrich (St. Louis, MO).
Recombinant TGF-1 was obtained from R&D Systems (Minneapo-
lis, MN). Enhanced chemiluminescence substrate (SuperSignal West
Pico Chemiluminescent Substrate, Pierce) was purchased from
Pierce (Rockford, IL).
Isolation and Culture of Primary
Corneal Fibroblasts
Normal and homozygote primary corneal fibroblasts were prepared
using previously described methods.35 Donor confidentiality was main-
tained in accordance with the Declaration of Helsinki, and the conduct
of the study was approved by the Severance Hospital IRB Committee
(CR04124), Yonsei University. GCD2 was diagnosed by DNA sequence
analysis for TGFBI gene mutations. After removal of the corneal button
for keratoplasty, the remaining corneal rims were harvested for normal
corneal fibroblast culture. Medical records of donors from the eye bank
of Yonsei University Severance Hospital did not show any genetic or
systemic metabolic disease. Fibroblasts grown from pieces of corneal
rims were treated as healthy controls, and DNA sequencing analysis
was performed to verify genetic normality of the BIGH3 gene. The
healthy human corneal fibroblast cells36 were cultured in DMEM sup-
plemented with 10% fetal bovine serum at 37°C in a humidified
incubator with 95% air and 5% CO2.
Cell Treatment with Lithium
Lithium was freshly dissolved in phosphate-buffered saline (PBS;
Gibco-BRL, Carlsbad, CA) at room temperature before use. To examine
the effects of lithium on TGFBIp protein expression, corneal fibro-
blasts were incubated with 10 to 100 mM LiCl and then analyzed by
immunoblot analysis.
RNA Isolation and RT-PCR
For the amplification of TGFBI and -actin, total RNA was isolated from
corneal fibroblasts by extraction in reagent (Trizol; Invitrogen Life Tech-
nologies, Carlsbad, CA). cDNA synthesis and DNA amplification were
performed (Superscript One-Step RT-PCR System; Invitrogen Life Tech-
nologies) and primers (Table 1). Amplification products were visualized
by electrophoresis in 1.2% agarose gels containing ethidium bromide.
Real-Time PCR
Primers for the human TGFBI and -actin specific genes were de-
signed according to the published sequences available in GenBank
using Primer3, as shown in Table 1. For the analysis of each sample,
gene expression levels were calibrated using -actin expression levels
as an internal control. Two micrograms of total RNA was reverse-
transcribed into cDNA using reverse transcriptase (Superscript II; In-
vitrogen) and an Oligo (dT) primer (Invitrogen). The cDNA reaction
was amplified in triplicate by real-time PCR (Exicycler; Bioneer,
Deajeon, South Korea) in a final volume of 50 L using SYBR Green
master mix reagent (AccurPower GreenStar qPCR PreMix; Bioneer)
and appropriate software (Exicycler version 3.1; Bioneer). -Actin, a
constitutively expressed housekeeping gene, was amplified under the
same conditions and used to normalize reactions. To ensure the spec-
ificity of the reaction, the size of the PCR product for each gene was
verified by 1.3% agarose gel electrophoresis. Results were evaluated by
data analysis with spreadsheet software (Excel; Microsoft, Redmond,
WA). All PCRs were performed under the following conditions: 2
minutes at 50°C, 5 minutes at 95°C, and 40 cycles of 15 seconds at
95°C and 45 seconds at 58°C in 96-well optical reaction plates (Bion-
eer). The specificity of amplicons was verified by melting curve anal-
ysis (60°C–95°C) after 40 cycles and agarose gel electrophoresis. Two
replicates for each sample were used for real-time PCR analysis, and
three technical replicates were analyzed for each replicate. Results of
quantitative RT-PCR were assessed by t-test.
Preparation of Cell Lysates, Immunoprecipitation,
and Immunoblot Analysis
Cell lysates from corneal fibroblasts were prepared in radioimmunopre-
cipitation assay buffer (RIPA buffer; 150 mM/L NaCl, 1% NP-40, 0.5%
deoxycholate, 0.1% SDS, 50 mM/L Tris-HCl, pH 7.4) containing protease
inhibitors (Complete Mini Protease Inhibitor Cocktail Tablet, catalog no.
1836170; Roche, Indianapolis, IN) and phosphatase inhibitors (PhosSTOP,
catalog no. 04906845001; Roche). Crude cell lysates were centrifuged at
10,000g for 10 minutes at 4°C to remove nuclear fragments and tissue
debris. A portion of the supernatant was used to determine the total
protein concentration using a bicinchoninic acid kit (Pierce).
Total cell lysate (5 mg protein) was subjected to immunoprecipi-
tation with anti-GSK-3 and anti-Smad3 antibodies, as indicated, over-
night at 4°C with gentle agitation, followed by incubation (Protein A/G
TABLE 1. Primer Sequences Used for RT-PCR and Real-Time PCR Analysis
Gene Sequence Accession No.
Amplicon
Length (bp)
Analysis
Method
TGFBI F: 5-AGCAGCCCTACCACTCTCAA-3 NM_000358 196 RT-PCR
R: 5-GACATTGCTGACCAGGGAGT-3
-Actin F: 5-GGACTTCGAGCAAGAGATGG-3 NM_001101 234
R: 5-AGCACTGTGTTGGCGTACAG-3
TGFBI F: 5-GTCCACAGCCATTGACCTTT-3 NM_000358 82 Real-time PCR
R: 5-ACCGCTCACTTCCAGAGAGA-3
-Actin F: 5-GGCATCCTCACCCTGAAGTA-3 NM_001101 65
R: 5-AGGTGTGGTGCCAGATTTTC-3
F, forward primer; R, reverse primer.
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Plus-Agarose; Invitrogen) for 2 to 4 hours at 4°C. After binding, the
beads were washed extensively three times with RIPA buffer and then
mixed with 2 SDS sample buffer and boiled for 5 minutes.
For immunoblot analysis, total cellular protein was subjected to elec-
trophoresis on 10% Tris-glycine SDS polyacrylamide gels. Proteins were
transferred onto polyvinylidene difluoride membranes (Millipore Corp.,
Bedford, MA), blocked in 5% dry milk in Tris-buffered saline containing
Tween-20 (TBS-T) (0.02 M Tris/0.15 M NaCl, pH 7.5, 0.1% Tween 20) at
room temperature for 1 hour, washed three times with TBS-T, and incu-
bated with antibodies against TGFBIp (0.2 g/mL; catalog no. AF2935;
R&D Systems), -actin (1:5000 dilution; catalog no. A-5441; Sigma-Al-
drich), and GSK-3/, pGSK-3/, Smad3, and pSmad3 (1:1000 dilution;
Cell Signaling Technology, Beverly, MA) overnight at 4°C. After three
washes with TBS-T, blots were incubated with HRP-conjugated secondary
antibody (anti-mouse IgG [1:5000 dilution; catalog no. NA931V] or anti-
rabbit IgG [1:5000 dilution; catalog no. NA934V]; Amersham Pharmacia
Biotechnology, Piscataway, NJ) at room temperature for 1 hour. Western
blot analysis was visualized using enhanced chemiluminescence (Pierce).
Immunoreactive protein bands were scanned at two intensities, and the
optical densities of the bands were quantified computationally with the
use of ImageJ software (developed by Wayne Rasband, National Institutes
of Health, Bethesda, MD; available at http://rsb.info.nih.gov/ij/index.html).
The background was corrected through subtraction, and protein levels
were normalized relative to the intensity of the corresponding -actin
protein bands.
Cell Viability
Corneal fibroblasts were plated in 96-well plates at a density of 10,000
cells/well and incubated overnight. Cell proliferation was determined
(CellTiter 96 AQueous One Solution Reagent Cell Proliferation Assay
Kit; Promega, Madison, WI) and tetrazolium (3-[4,5-dimethylthiazol-2-
yl]-5-(3-carboxymethoxyphenyl)-2-[4-sulfophenyl]-2H-tetrazolium, in-
ner salt; MTS) (catalog no. G3580; Promega). Briefly, the culture me-
dium was removed, and 20 L MTS solution was added to each well
containing 100 L culture medium. Cultures were incubated at 37°C
for 2 to 4 hours under 95% humidity and 5% CO2. Optical density was
measured at 450 nm using a plate reader.
Statistical Analysis
The results were evaluated statistically for significance (P 0.05) using
one-way analysis of variance followed by the Newman-Keuls multiple
comparison test. Data are expressed as mean  SD. All data were
processed using scientific graphing analysis software (Prism, version
4.0; GraphPad Software Inc., San Diego, CA).
RESULTS
TGFBIp Expression Is Downregulated by Lithium
in Corneal Fibroblasts
Recently, several studies have revealed that inhibitors of GSK-3
can downregulate TGFBIp expression by blocking TGF- sig-
naling.30–32 To test this hypothesis, we analyzed levels of
TGFBIp in primary corneal fibroblasts treated with lithium, a
known GSK-3 inhibitor. Western blot analysis showed that
lithium reduced levels of TGFBIp in a dose- (Fig. 1A) and a
time-dependent manner (Fig. 1B). We next examined the ef-
FIGURE 1. LiCl reduces TGFBIp expression in primary cultured corneal fibroblasts. (A) A healthy corneal
fibroblast cell line was treated with the indicated amounts of LiCl or KCl for 12 hours. KCl was used as a
control. The levels of TGFBIp were assessed by Western blot analysis. (B) A healthy corneal fibroblast cell
line was treated with 10 mM LiCl for the indicated times. The levels of TGFBIp were assessed by Western
blot analysis. (C) The level of TGFBI mRNA in healthy corneal fibroblast cells treated with the indicated
concentrations of LiCl for 12 hours was measured by RT-PCR. (D) Quantification of the data presented in
(C). (E) WT and HO primary corneal fibroblasts were treated with the indicated amounts of LiCl for 12
hours. The levels of TGFBIp were assessed by Western blot analysis. -Actin served as a loading control.
(F) Quantification of the data presented in (E). All signals were quantified using NIH Image J. Values
represent the mean  SD of at least three independent experiments. Statistical analysis was performed
using one-way analysis of variance followed by the Newman-Keuls multiple comparison test. *P  0.05;
**P  0.01 with LiCl versus without LiCl.
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fects of lithium on TGFBI mRNA expression. Quantitative RT-
PCR showed that treatment with LiCl for 12 hours resulted in
decreased TGFBI mRNA expression in a dose-dependent man-
ner (Fig. 1C). Quantitative analysis revealed that treatments
with 10 mM, 30 mM and 50 mM LiCl significantly decreased
TGFBI mRNA expression by approximately 81.43%  8.73%,
74.10%  4.41%, and 70.60%  2.69%, respectively, relative to
-actin, which was used as a control (P  0.05) (Fig. 1D).
Taken together, these results suggest that TGFBIp regulation
occurs at the level of transcription.
In addition, we analyzed the expression of mut-TGFBIp in
GCD2 homozygous (HO) corneal fibroblasts after lithium treat-
ment to test whether the inhibitor also blocked the expression
of GCD2-linked mutant TGFBIp. Treatment of wild-type (WT)
corneal fibroblasts with 10, 30, and 50 mM LiCl for 12 hours
reduced TGFBIp levels by 78.37%  10.00%, 41.43%  4.25%,
and 24.33%  4.14%, respectively, compared with untreated
fibroblasts (P  0.01) (Figs. 1E, 1F). Further, LiCl treatment at
the same concentrations decreased TGFBIp expression by ap-
proximately 61.96%  3.51%, 30.21%  3.63%, and 16.75% 
2.74%, respectively, in GCD2 HO corneal fibroblasts (P 0.01)
(Figs. 1E, 1F).
Induction of TGFBIp Expression by TGF-1 Is
Inhibited by Lithium Treatment
TGFBIp was first identified in an adenocarcinoma cell line,
where it was found to be upregulated on TGF- treatment.
Therefore, we examined whether TGFBIp expression could
also be induced by TGF- treatment in a corneal fibroblast cell
line. Our data demonstrate that TGF-1 induced the expression
of TGFBIp in a dose- (Fig. 1A) and a time-dependent manner
(Fig. 1B). Next, to investigate the effect of lithium on the
induction of TGFBIp expression, corneal fibroblasts pretreated
with TGF-1 for 2 hours were subsequently treated with 10,
30, and 50 mM LiCl for 12 hours. As shown Figures 2C and 2D,
10, 30, and 50 mM lithium inhibited TGF-–induced TGFBIp
levels by 58.11%  9.06%, 32.46%  5.79%, and 14.80% 
3.94%, respectively, compared with samples treated only with
TGF-1.
Lithium Inhibits TGF- Signaling by Inhibition of
Smad3 Phosphorylation
At least two mechanisms are conceivable for how LiCl de-
creases TGFBIp protein levels: LiCl enhances TGFBIp degrada-
tion or decreases TGFBIp biosynthesis. After identification of
Smad3/GSK-3 complexes, Guo et al.37 suggested that GSK-3
can activate Smad3. Further, lithium is well established as a
GSK-3 inhibitor. Therefore, we examined the effects of LiCl on
TGFBIp expression by investigating the TGF- signaling path-
way. Treatment of corneal fibroblasts with 10, 30, and 50 mM
LiCl reduced Smad3 phosphorylation (S423/425) by 46.09% 
5.53%, 31.29%  6.70%, and 20.37%  6.29%, respectively
(Figs. 3A, 3B). In addition, LiCl interacts with GSK-3/ and
negatively regulates its activity (Fig. 3A, 3C, 3D). Treatment of
corneal fibroblasts with 10, 30, and 50 mM LiCl for 12 hours
increased GSK-3 phosphorylation significantly by 317.3% 
38.00%, 401.0%  43.86%, and 512.0%  23.90%, respectively
(P 0.01; Fig. 3A, 3C). GSK-3 phosphorylation also increased
significantly (Figs. 3A, 3D). Taken together, these results sug-
gest that the observed lithium-induced decrease in TGFBIp
levels was caused by the inhibition of TGF- signaling.
Interaction of Smad3 with GSK-3
To examine whether Smad3 interacts with GSK-3 in corneal
fibroblasts, we used healthy corneal fibroblasts. Endogenous
GSK-3 was detected by the anti-GSK-3 antibody. When the
lysates were immunoprecipitated with the anti-GSK-3 anti-
body, Smad3 was detected in the GSK-3 immune complex
(Fig. 4A, lane 3). To examine the effect of LiCl on the interac-
tion between GSK-3 and Smad3, we used lysates of corneal
fibroblasts treated with 0, 30, and 50 mM LiCl concentration.
When the lysates were immunoprecipitated with the anti-
Smad3 antibody, detection of GSK-3 increased in the GSK-3
FIGURE 2. TGF-1–induced TGFBIp expression is inhibited by LiCl. (A) A healthy corneal fibroblast cell
line was treated with the indicated amounts of TGF-1 for 12 hours. Cell lysates and media were analyzed
for TGFBIp by Western blot analysis. (B) A healthy corneal fibroblast cell line was treated with 5 ng/mL
TGF-1 for the indicated times. TGFBIp levels were analyzed by Western blot. (C) Healthy corneal
fibroblasts pretreated with 5 ng/mL TGF-1 for 2 hours were cultured with 10 to 50 mM LiCl for 12 hours.
TGFBIp levels were analyzed by Western blot. (D) Quantification of data presented in (C). The levels of
TGFBIp were quantified using NIH Image J software and normalized to -actin. Values represent the
mean  SD of three independent experiments. Statistical analysis was performed using one-way analysis
of variance followed by the Newman-Keuls multiple comparison test. *P  0.05; **P  0.01 with LiCl
versus without LiCl.
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immune complex obtained by LiCl treatment compared with
the GSK-3 immune complex from no LiCl treatments (Fig. 4B,
lane 3). In our hands, interactions between Smad3 and GSK-3
were not different during treatment with 30 and 50 mM LiCl.
Together, these results suggest that lithium may regulate the
intracellular TGF- signaling by the interactions of GSK-3 and
Smad3 proteins.
Lithium Induces Autophagy
Reports have shown that lithium induces autophagy by way of
the PI3K signaling pathway.38 Previously, we demonstrated
that the activation of autophagy enhances the cytosolic clear-
ance of accumulated mut-TGFBIp in primary cultured GCD2
corneal fibroblasts (Choi et al., manuscript submitted). Thus,
we investigated whether lithium activates autophagy in cor-
neal fibroblasts. During autophagy, a cytosolic form of the
microtubule-associated protein light chain 3-I (LC3-I) is conju-
gated to phosphatidylethanolamine to form LC3 phosphatidyle-
thanolamine conjugate (LC3-II), which is recruited to autopha-
gosomal membranes. Both the ratio of LC3-II to LC3-I and the
amount of LC3-II can be used to monitor autophagosome
formation.39,40 Therefore, it was used to monitor autophagy in
this study. After treatment with 10, 30, and 50 mM LiCl for 12
hours in corneal fibroblasts, the ratio of LC3-II/LC3-I increased
by 1.09  0.1-, 1.60  0.19-, and 2.56  0.24-fold, respectively
(P  0.01), over the control (Figs. 5A, 5B). These results
suggest that lithium not only inhibits TGFBIp expression, it
also enhances the cytosolic clearance of accumulated mut-
TGFBIp in corneal fibroblasts.
Lithium Is Not Toxic to Primary Cultured
Corneal Fibroblasts
To assess the cytotoxicity of LiCl, primary corneal fibroblasts
were incubated with LiCl, and cell viability was measured by
the MTT assay. As shown in Figure 6, cell viability was greater
FIGURE 3. LiCl inhibits TGF- signal-
ing by promoting Smad3 dephos-
phorylation. (A) Healthy corneal fi-
broblast cells were treated with the
indicated amounts of LiCl for 12
hours. Levels of pSmad3 (S423/425),
Smad3, pGSK-3/, p--catenin, and
-catenin were assessed by Western
blot. (B) Quantification of pSmad3
(S423/425) levels using NIH Image J
software and normalized to total
Smad3. (C) Healthy corneal fibro-
blast cells were treated with the in-
dicated amounts of LiCl for 12 hours.
Levels of pGSK-3 were assessed by
Western blot, quantified using NIH
Image J software, and normalized to
total GSK-3. (D) Healthy corneal fi-
broblasts were treated with the indi-
cated amounts of LiCl for 12 hours.
Levels of pGSK-3 were quantified
using NIH Image J software and nor-
malized to total GSK-3/. Values
represent the mean  SD of three
independent experiments. Statistical
analysis was performed using one-
way analysis of variance followed by
the Newman-Keuls multiple compar-
ison test. *P  0.05; **P  0.01 with
LiCl versus without LiCl.
FIGURE 4. Physical interaction be-
tween GSK-3 and Smad3 in healthy
corneal fibroblasts treated with LiCl.
(A) The interaction between GSK-3
and Smad3 was determined by coim-
munoprecipitation (co-IP) of GSK-3
using an anti-GSK-3/ antibody fol-
lowed by Western blot with anti-
Smad3 antibody. (B) Direct interac-
tion between Smad3 and GSK-3was
determined by co-IP of Smad3 using
an anti-pSmad3 antibody followed by
Western blot with anti-GSK-3/ an-
tibody. C, increased interaction be-
tween pSmad3 and pGSK-3 by LiCl.
The interaction between GSK-3 and
Smad3 was highly enhanced in cor-
neal fibroblasts treated with the indi-
cated LiCl concentration. Direct interaction between Smad3 and GSK-3was determined by co-IP of Smad3 using an anti-pSmad3 antibody followed
by Western blot with anti-GSK-3/ antibody. As a control, normal IgG alone was directly immunoprecipitated with anti-GSK-3 and anti-Smad3
(lanes 4 and 5), respectively. As a control, normal IgG alone was directly immunoprecipitated with anti-GSK-3 and anti-Smad3.
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than 98% after treatment with four different doses of LiCl,
indicating that LiCl did not result in significant cell death with
the concentrations tested. Taken together, the observed atten-
uating effects of LiCl on TGFBIp expression were not due to
corneal fibroblast cell death.
DISCUSSION
There is no prevention or cure for TGFBI-linked corneal
dystrophy. Thus, there is great hope for the development of
novel therapies. To our knowledge, this is the first study
describing the impact of lithium on specimens from TGFBI-
linked corneal dystrophy patients. Here, we show an effec-
tive decrease in TGFBIp expression with lithium without
cytotoxic effects. Furthermore, we confirmed lithium’s role
in the stimulation of autophagy in corneal fibroblasts. These
findings strongly suggest that lithium may be used for the preven-
tion or treatment for TGFBI-linked corneal dystrophies.
TGFBI is a secreted protein induced by TGF- in human
adenocarcinoma cells and other human cell types.1 This pro-
tein exhibits tumor suppressive function.2,3 We have also
shown that TGFBIp expression can be induced by TGF- in a
dose-dependent manner and that lithium inhibits this induction
in corneal fibroblasts. Thus, these results suggest that lithium
may also have a potential role in inhibiting the TGF- signaling
pathway.
Lithium was discovered in 1996 by Klein and Melton as a
reversible GSK-3 inhibitor.19 Studies have established that lith-
ium reduces GSK-3 activity in two ways.41 As a direct inhibitor,
lithium competes with magnesium ions for GSK-3 binding.42
Alternatively, as an indirect inhibitor, lithium increases the
inhibitory N-terminal serine phosphorylation of GSK-3, which
inactivates enzyme function. More recently, Millet et al.43 have
suggested that GSK-3 activity negatively regulates the TGF-
signaling pathway.43 These results suggest that lithium can
affect genes regulated by TGF- signaling. Based on these
results, we hypothesized that a GSK-3 inhibitor can be used as
a potential therapeutic agent for TGFBI-linked corneal dystro-
phies. Therefore, we examined the role of lithium on the
expression of TGFBIp in WT and GCD2 corneal fibroblasts.
Here, we have shown that lithium may prevent or treat TGFBI-
linked corneal dystrophies by inhibiting TGF- signaling.
The TGF- signaling pathway has been implicated as a
regulator in numerous cellular and physiological processes,
including extracellular matrix homeostasis.16 This pathway is
initiated by the binding of TGF- to type I (TRI) and type II
TGF- receptors (TRII), both of which are serine/threonine
kinases. The activated receptor complex phosphorylates the
downstream transcription factors Smad2 and Smad3, leading to
their association with Smad4. The Smad complex then be-
comes concentrated in the nucleus and regulates the expres-
sion of target genes.32 These steps are tightly controlled to
ensure that Smad2/3 transmits signals from the plasma mem-
brane to the nucleus. Therefore, the decrease in TGFBIp ex-
pression induced by lithium treatment is consistent with the
observed reduction in Smad3 phosphorylation in the presence
of the inhibitor (Fig. 3A).
However, although controlling Smad activity is crucial for
proper TGF- signaling and its related factors, the specific
mechanism(s) involved in the lithium-induced decrease in
Smad3 phosphorylation remains unknown. More recently, Guo
et al.37 have shown that nonactivated Smad3, but not Smad2,
undergoes proteasome-dependent degradation caused by the
concerted action of the scaffolding protein Axin and its asso-
ciated kinase, GSK-3. Smad3 interacts physically with Axin
and GSK-3 only in the absence of TGF-. Reduction in the
expression or activity of Axin/GSK-3 leads to increased
Smad3 stability and transcriptional activity without affecting
TGF- receptors or Smad2. In contrast, overexpression of these
proteins promotes Smad3 basal degradation and desensitizes
cells to TGF-.37 However, in this study, the mechanism of
TGFBIp reduction in response to lithium may be mediated by
the inhibition of TGF- signaling through decreased Smad3
phosphorylation without a reduction in total Smad3 protein. In
addition, Millet et al.43 demonstrated that TGF- induces phos-
phorylation at three sites within the Smad3 linker region in
addition to two C-terminal residues. GSK-3 is responsible for
phosphorylating one of these sites, namely Ser204. Although
FIGURE 5. Lithium induces autophagy
LiCl in corneal fibroblasts. (A) A healthy
corneal fibroblast cell line was treated
with the indicated amounts of LiCl for 12
hours. Protein levels of LC3 were as-
sessed by Western blot. (B) LC3-II levels
were quantified using NIH Image J soft-
ware and normalized to LC3-I. Values
represent the mean SD of three inde-
pendent experiments. Statistical analysis
was performedusing one-way analysis of
variance followed by theNewman-Keuls
multiple comparison test. **P  0.01
with LiCl versus without LiCl.
FIGURE 6. LiCl is not toxic to corneal
fibroblasts. WT (A) and HO (B) corneal
fibroblasts were treated with different
concentrations of LiCl (0–100 mM) for
the indicated times (12–36 hours). Cell
viability was analyzed by the MTT as-
say. Cell viability was calculated using
the following: MTS optical density
(OD) value of sample/MTS OD value of
control (cells treated with PBS).
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we did not assay Smad3 (Ser204) phosphorylation, our results
showed decreased Smad3 phosphorylation at S423/425 and
increased interaction between Smad3 and GSK-3 in lithium-
treated cells. Thus, our findings reveal a novel aspect of Smad3
signaling that controls the final amplitude of TGFBI expression
and the cellular responses to TGF-.
The proteasome and autophagy/lysosomal pathways are the
major routes for the clearance of cytosolic protein. Although
the narrow proteasome barrel precludes entry of oligomers/
aggregates of aggregate-prone intracellular proteins, such sub-
strates can be degraded by autophagy. We have previously
shown that TGFBIp is degraded by the lysosome/autophagy
degradation pathway, and its degradation is delayed in GCD2
corneal fibroblasts. Further, the autophagy inducer rapamycin
reduced the levels of cytosolic mutant TGFBIp and attenuated
its toxicity in GCD2 homozygous corneal fibroblasts. Further-
more, these data demonstrate that the aggregate-prone form of
mutant TGFBIp, unlike the WT protein, is strongly dependent
on autophagy for clearance. In addition, we found that mutant
TGFBIp accumulates in lysosomes or autolysosomes in GCD2
corneal fibroblasts because of an impairment in autophagy
(Choi et al., manuscript submitted). Therefore, these findings
suggest that an autophagy inducer can also be used as a ther-
apeutic drug for TGFBI-linked corneal dystrophies in the fu-
ture.
The autophagy pathway is strongly regulated by levels of
IP3, which acts as an endogenous autophagy inhibitor. In
contrast, lithium promotes autophagy by blocking IP3 activ-
ity.38,44,45 In this study, we found that lithium induces au-
tophagy in corneal fibroblasts. Although we did not determine
the levels of decreased TGFBIp after the activation of au-
tophagy with lithium, these findings suggest the therapeutic
benefits of lithium in TGFBI-linked corneal dystrophies. In fact,
given that lithium did not induce significant death in corneal
fibroblasts even at very high concentrations (100 mM), it is
highly likely that lithium can be used as a therapeutic agent for
treating GCD2.
Studies have also demonstrated that the cytoprotective ef-
fects of lithium against oxidative stressors are dependent on
the blockage of cytochrome c release and caspase-3 activa-
tion.46 Previously, we showed that oxidative stress is involved
in the pathogenesis of GCD2.46 One possible relationship be-
tween GSK-3 activity and oxidative stress has been well de-
scribed.47 Oxidative stress may promote degeneration and
ultimate cell death through DNA fragmentation, lipid per-
oxidation, and induction of mitochondrial proapoptotic path-
ways involving caspases and GSK-3.48 In addition, efforts to
understand the molecular mechanisms underlying the resis-
tance of cells to hydrogen peroxide-induced oxidative stress
have shown that reduced GSK-3 activity may be essential to
cell survival. In addition, the treatment of cells with lithium as
a GSK-3 inhibitor resulted in increased resistance to hydrogen
peroxide-induced oxidative stress.49 Interestingly, evidence ex-
ists showing that GSK-3 inhibition specifically protects cells
from intrinsic oxidative stress.50 Thus, GSK-3 plays an impor-
tant role in PI3K- and Akt-mediated cell survival pathways.
Lithium is known to have antiapoptotic effects by reducing the
expression of multiple apoptotic proteins, such as p53, Bax,
and caspases,23,51 and by increasing Bcl-2 levels.52 Therefore,
we also suggest that lithium treatment of TGFBI-linked corneal
dystrophies may have multifunctional benefits. Ultimately, lith-
ium treatment may be effective in regulating TGF- signaling,
autophagy, and oxidative stress in numerous diseases.
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